T1	Premise 878 1063	Numeric rating scale scores for pain intensity in group 1 and group 2 were significantly lower than those in group 3 at T(0-12) (P < .001); T(12-24) (P < .001); and T(24-48) (P < .001).
T2	Premise 1064 1224	When group 1 with group 2 were compared, numeric rating scale scores were significantly lower in group 1 than in group 2 during the period of T(0-12) (P < .001)
T3	Premise 1225 1307	but were not significantly different at T(12-24) (P = .68) and T(24-48) (P = .10).
T4	Premise 1308 1410	Analgesic cost and hospital stay were significantly lower in treated groups than in the placebo group.
T5	Premise 1411 1537	No significant difference was observed in quality of life and adverse events between the treated groups and the placebo group.
T6	Claim 1538 1698	CRO is effective, safe, and cost-effective in the control of postoperative pain after transarterial chemoembolization for patients with inoperable liver cancer.
R1	Partial-Attack Arg1:T3 Arg2:T2	
R2	Support Arg1:T4 Arg2:T6	
R3	Support Arg1:T2 Arg2:T6	
R4	Support Arg1:T5 Arg2:T6	
R5	Support Arg1:T1 Arg2:T6	
